Table 2.
Impact of OCM on adherence to oral drugs for CML, prostate cancer, and hormonal therapy for breast cancer
| Proportion of days covered | No. of episodes |
OCM proportion of days covered |
Comparison proportion of days covered |
Impact estimatesa |
||||
|---|---|---|---|---|---|---|---|---|
| OCM | Comparison | Baseline, % | Intervention, % | Baseline, % | Intervention, % | DID (90% CI), % | P b | |
| All tyrosine kinase inhibitors | 12 152 | 13 329 | 87.6 | 86.1 | 88.1 | 86.8 | −0.3 (−1.2 to 0.6) | .60 |
| Enzalutamide or abiraterone | 23 050 | 28 126 | 88.6 | 84.5 | 89.1 | 84.5 | 0.4 (−0.3 to 1.2) | .34 |
| Hormonal therapy for breast cancer | 237 803 | 252 554 | 90.4 | 90.8 | 90.7 | 91.1 | 0.0 (−0.2 to 0.2) | .86 |
Full model results are included in Supplementary Tables 5-7 (available online). CI = confidence interval; CML = chronic myelogenous leukemia; DID = difference-in-difference estimate; OCM = Oncology Care Model intervention group.
Impact estimates and 2-sided P values based on difference-in-differences regression analysis.